OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Long-Term Investments
OSE Immunotherapeutics SA
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Long-Term Investments
€6.4m
|
CAGR 3-Years
90%
|
CAGR 5-Years
86%
|
CAGR 10-Years
71%
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Long-Term Investments
€10.3m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Investments
€3.4m
|
CAGR 3-Years
34%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Long-Term Investments?
Long-Term Investments
6.4m
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Long-Term Investments amounts to 6.4m EUR.
What is OSE Immunotherapeutics SA's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
71%
Over the last year, the Long-Term Investments growth was 603%. The average annual Long-Term Investments growth rates for OSE Immunotherapeutics SA have been 90% over the past three years , 86% over the past five years , and 71% over the past ten years .
You don't have any saved screeners yet